T2D PrimeView goes viral
A Nature Reviews 'PrimeView' on type 2 diabetes just went viral, using a boat‑race visual to map epidemiology to therapy and flagging obesity‑driven T2D as a global epidemic tied to insulin resistance and β‑cell dysfunction (diagnostics: HbA1c, OGTT). ( ) The primer highlights emerging therapies — GLP‑1s (semaglutide), dual agonists (tirzepatide) and pipeline triple‑agonists — and calls for precision medicine, CGM data analytics, and outcomes beyond A1c, noting early‑onset cases (<40) show faster β‑cell decline. (x.com)
The Primer "Type 2 diabetes mellitus" was published in Nature Reviews Disease Primers on 19 March 2026 and is authored by a multinational team led by Melanie J. Davies and Ildiko Lingvay with contributors from Leicester, Seoul National University, Scripps Health and UT Southwestern. (nature.com) The PrimeView compresses recent burden estimates: an estimated 828 million adults had diabetes in 2022, roughly 40% of people with diabetes remain undiagnosed globally, and diabetes accounted for about 9.3% of global deaths in 2024. (nature.com) The visual and accompanying Primer enumerate specific next‑generation agents in the pipeline — examples named include retatrutide, ecnoglutide, orforglipron, survodutide and amycretin — and the authors state that several new drugs are expected to be licensed within the next decade. (nature.com) Authors explicitly recommend integrating precision‑medicine approaches with digital technologies such as continuous glucose monitoring and advanced data analytics to supplement A1c and refine therapeutic decisions. (nature.com) The Primer highlights the rise of early‑onset T2D (diagnosis <40 years) and cites evidence that these cases exhibit more aggressive insulin resistance and faster β‑cell decline, a pattern corroborated in recent analyses of early‑onset cohorts. (nature.com) Contemporaneous real‑world studies cited alongside the Primer show tirzepatide use in large US cohorts (n≈140,308) was associated with lower hazards of all‑cause mortality and major adverse cardiovascular and kidney events compared with earlier GLP‑1 receptor agonists. (jamanetwork.com)
